{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:41:54Z","timestamp":1782409314148,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013298","name":"Sociedad Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.reumae.2026.502104","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:19:15Z","timestamp":1775823555000},"page":"502104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of rheumatoid arthritis-associated interstitial lung disease: What is new since the 2022 SER-SEPAR recommendations?"],"prefix":"10.1016","volume":"22","author":[{"given":"Javier","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Asunci\u00f3n","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Villaverde Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Candelas Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2026.502104_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11926-024-01155-8","article-title":"Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): update on prevalence, risk factors, pathogenesis, and therapy","volume":"26","author":"Sullivan","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reumae.2026.502104_bib0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/acr2.11736","article-title":"Clinical course of interstitial lung disease in patients with rheumatoid arthritis","volume":"6","author":"Matteson","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0015","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semarthrit.2023.152187","article-title":"Survival of adults with rheumatoid arthritis associated interstitial lung disease - A systematic review and meta-analysis","volume":"60","author":"Farquhar","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.reuma.2022.02.009","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis","volume":"18","author":"Rodr\u00edguez Portal","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.reumae.2026.502104_bib0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.reuma.2022.03.005","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.reumae.2026.502104_bib0035","series-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide. Actualizaci\u00f3n","year":"2025"},{"key":"10.1016\/j.reumae.2026.502104_bib0040","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2026.502104_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.reumae.2026.502104_bib0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/OARRR.S462662","article-title":"Safety of tocilizumab on rheumatoid arthritis in patients with interstitial lung disease","volume":"16","author":"Otsuji","year":"2024","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0055","first-page":"451","article-title":"Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review","volume":"43","author":"Suzuki","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0060","article-title":"Comparative effectiveness of tocilizumab versus rituximab in RA-ILD: a emulated target trial","author":"Wu","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.reumae.2026.502104_bib0065","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0070","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40744-021-00332-w","article-title":"Baricitinib and the risk of incident interstitial lung disease: a descriptive clinical case report from clinical trials","volume":"8","author":"Salvarani","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2026.502104_bib0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/s10165-010-0280-z","article-title":"Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA","volume":"20","author":"Shidara","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0080","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.reumae.2026.502104_bib0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/jcm12030957","article-title":"Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","volume":"12","author":"Venerito","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0095","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0100","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00296-021-04835-1","article-title":"A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease","volume":"41","author":"Cronin","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2026.502104_bib0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-024-00374-x","article-title":"Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study","volume":"8","author":"Tsujii","year":"2024","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.resinv.2023.02.007","article-title":"Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year","volume":"61","author":"Mochizuki","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.reumae.2026.502104_bib0115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.reumae.2026.502104_bib0120","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d\u2019Alessandro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.reumae.2026.502104_bib0125","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2026.502104_bib0130","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1093\/rheumatology\/keaf314","article-title":"Baricitinib in rheumatoid arthritis-interstitial lung disease: national multicenter study of 72 patients and literature review","volume":"64","author":"Serrano-Combarro","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Narv\u00e1ez","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2026.502104_bib0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","volume":"119","author":"Atienza-Mateo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0145","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.reumae.2026.502104_bib0150","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.3390\/jcm13195871","article-title":"The therapeutic efficacy of abatacept for rheumatoid arthritis-associated interstitial lung disease: insights from a 12-month trial using semi-quantitative chest high-resolution Computed Tomography imaging","volume":"13","author":"Shoda","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung diseaseof rheumatoid arthritis: a systematic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2026.502104_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152795","article-title":"Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials","volume":"74","author":"Dieud\u00e9","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.46497\/ArchRheumatol.2024.10199","article-title":"Rituximab for rheumatoid arthritis-related interstitial lung disease: a systematic review and meta-analysis","volume":"39","author":"Krishna Boppana","year":"2024","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0175","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0180","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003487","article-title":"Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"9","author":"Yuan","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2026.502104_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152735","article-title":"Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: a propensity score-matched, active-comparator, new-user study","volume":"73","author":"Frideres","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0190","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152312","article-title":"Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease","volume":"64","author":"Juge","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0205","article-title":"Antifibrotics in the management of rheumatoid arthritis-associated interstitial lung disease: prospective real-world experience from an interstitial lung disease clinic in India","volume":"16","author":"Behera","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.reumae.2026.502104_bib0210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.63032\/POPM9413","article-title":"Antifibrotics in rheumatoid arthritis-associated interstitial lung disease \u2014 real-world data from a nationwide cohort","volume":"3","author":"Duarte","year":"2024","journal-title":"ARP Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0215","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.3390\/jcm13237074","article-title":"Real-world clinical effectiveness and safety of antifibrotics in progressive pulmonary fibrosis associated with rheumatoid arthritis","volume":"13","author":"Narv\u00e1ez","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103804","article-title":"Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"24","author":"Narv\u00e1ez","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2026.502104_bib0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0230","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/rheumatology\/keac651","article-title":"Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0235","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease \u2014 improving outcomes over 25 years: a large multicentre UK study","volume":"60","author":"Kelly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0240","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2026.502104_bib0245","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2026.502104_bib0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00296-017-3781-7","article-title":"Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis","volume":"37","author":"Kim","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2026.502104_bib0255","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/resp.12234","article-title":"Predictors of mortality in rheumatoid arthritis-related interstitial lung disease","volume":"19","author":"Assayag","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.reumae.2026.502104_bib0260","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s10067-021-06040-8","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis","volume":"41","author":"Rojas-Serrano","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0265","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1093\/rheumatology\/keac208","article-title":"The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease","volume":"61","author":"Brooks","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0270","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.reumae.2026.502104_bib0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-024-01448-3","article-title":"Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study","volume":"24","author":"Shih","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease","volume":"85","author":"Antoniou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2026.502104_bib0285","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","article-title":"Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug","volume":"168","author":"Saketkoo","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0300","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","article-title":"Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study","volume":"60","author":"Ibfelt","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2026.502104_bib0305","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"52","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.reumae.2026.502104_bib0310","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.reumae.2026.502104_bib0315","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/alat clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.reumae.2026.502104_bib0320","article-title":"Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?","volume":"30","author":"Cassone","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.reumae.2026.502104_bib0325","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2026.502104_bib0330","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:17:46Z","timestamp":1778098666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574326000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2173574326000511"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502104","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of rheumatoid arthritis-associated interstitial lung disease: What is new since the 2022 SER-SEPAR recommendations?","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2026.502104","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Reumatolog\u00eda (SER), Colegio Mexicano de Reumatolog\u00eda (CMR) and Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502104"}}